NNK

• UNSPSC Description:

  NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser70 and c-Myc at Thr58 and Ser62 through activation of both ERK1/2 and PKCα[1]. NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure[2].

• Target Antigen:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nnk.html

• Purity:

  99.98

• Solubility:

  DMSO : ≥ 62.5 mg/mL

• Smiles:

  O=C(C1=CC=CN=C1)CCCN(C)N=O

• Molecular Weight:

  207.23

• References & Citations:

  [1]Jin Z, et al. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem. 2004;279(38):40209-40219.|[2]Castonguay A, et al. Lung tumorigenicity of NNK given orally to A/J mice: its application to chemopreventive efficacy studies. Exp Lung Res. 1991;17(2):485-499.|[3]Ge GZ, et al. Tobacco carcinogen NNK-induced lung cancer animal models and associated carcinogenic mechanisms. Acta Biochim Biophys Sin (Shanghai). 2015 Jul;47(7):477-87. |[4]Razani-Boroujerdi S, et al. Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility. Am J Respir Cell Mol Biol. 2007 Jan;36(1):13-9.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  64091-91-4